Mithra Releases Invitation to its General Shareholders’ Meeting
Mithra Releases Invitation to its General
Shareholders’ Meeting
Liege, Belgium, 25 April 2023 – 7:30
CET – Mithra (Euronext Brussels: MITRA), a company
dedicated to Women’s Health, today announces the invitation to its
general shareholders’ meeting that will be held on Tuesday
May 25 2023 at 2:00 PM (CEST).
The notice for the General Meeting including a
description of the formalities to participate in the meeting is
available on the website investors.mithra.com.
Admission requirements
As referred in the meeting’s invitation
published in the Belgian press, the right to participate in the
general shareholder’s meeting and to vote is subject to the prior
registration of the shares under the shareholder’s name on
11 May 2023 at midnight (CEST) (the
"Record Date"), either by way of registration on
the company’s share register, or either by way of registration in
book entry form in an account held with a settlement institution or
a certified account holder, without taking into account the number
of shares held by the shareholder at the day of the general
meeting. Only persons who are shareholders on the Record Date are
entitled to vote at the general meeting.
A certification is delivered to the shareholder
by the settlement institution or certified account holder which
certifies the number of dematerialized shares registered in its
accounts under the name of the shareholder on the Record Date, for
which the shareholder has expressed its intention to participate in
the general meeting.
The shareholder indicates his willingness to
participate in the General Meeting by 19 May 2023
at the latest. This must be done by email to
corporate.secretary@mithra.com, or by mail marked for the attention
of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue
Saint-Georges à 4000 Liège.
Right to ask questions
The directors answer questions that are asked by
the shareholders, in writing before the meeting, concerning their
report or the agenda, in accordance with legal provisions. These
questions may be asked prior to the General Meeting by email to the
address corporate.secretary@mithra.com or by mail marked for the
attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue
Saint-Georges à 4000 Liège. These questions must be received by the
Company on 19 May 2023 at the latest.
Further information relating to the abovementioned
right and the modalities for exercising them are available on the
Company's website (www.mithra.com).
Proxies
Any shareholder who wish to vote for that
meeting shall be represented by a proxy holder determined by the
Company.
Shareholders wishing to be represented must send
the completed and signed proxy form to the Company
on 19 May 2023 at the latest, by
email, fax or mail to Mithra’s headquarter.
Shareholders wishing to vote by mail must send
the completed and signed proxy form to the Company
on 19 May 2023 at the latest, by
email, fax or mail to Mithra’s headquarter.
Further information on the exercise of this
right is available on the Company’s website (www.mithra.com). The
proxy and voting forms may be obtained on the Company's website
(www.mithra.com) or upon request at the Company's registered
office, or by email to corporate.secretary@mithra.com.
Shareholders wishing to be represented must
comply with the registration and confirmation procedure described
above.
Available documents
All documents concerning the general meeting that
are required by law to be made available to shareholders as well as
the text of the amended articles of association following the
approval of the amendments proposed on the agenda may be consulted
on the Company's website (www.mithra.com) as from 25 April 2023. As
from the same date, shareholders have the right to consult these
documents on business days and during normal office hours, at the
Company's registered office and/or, upon display of their
securities, obtain copies of these documents free of charge.
Requests for copies may also be made, free of
charge, by mail (writing) marked for the attention Mithra
Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à
4000 Liège, or by email to corporate.secretary@mithra.com.
1 The form must be signed in writing or
electronically, with a qualified electronic signature within the
meaning of Regulation (EU) No 910/2014 of the European Parliament
and of the Council of 23 July 2014 on electronic identification and
trust services for electronic transactions in the internal market
and repealing Directive 1999/93/EC, as amended
********
For more information, please contact:
Alexandra Deschner: +32 (0)4
349 28 22 – investorrelations@mithra.com
About Mithra
Mithra (Euronext: MITRA) is a Belgian biotech
company dedicated to transforming Women’s Health by offering new
choices through innovation, with a particular focus on
contraception and menopause. Mithra’s goal is to develop products
offering better efficacy, safety and convenience, meeting women’s
needs throughout their life span. Mithra explores the potential of
the unique native estrogen estetrol in a wide range of applications
in women health and beyond. After having successfully launched the
first estetrol-based product in 2021, the contraceptive pill
Estelle®, Mithra is now focusing on its second product Donesta®,
the next-generation hormone therapy. Mithra also offers partners a
complete spectrum of solutions from early drug development,
clinical batches and commercial manufacturing of complex polymeric
products (vaginal ring, implants) and complex liquid injectables
and biologicals (vials, pre-filled syringes or cartridges) at its
technological platform Mithra CDMO. Active in more than 100
countries around the world, Mithra has an approximate headcount of
230 staff members and is headquartered in Liège, Belgium.
www.mithra.com
ESTELLE®, DONESTA® and MYRING® are registered
trademarks of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
- 2023-04-24_Mithra_Press-release_General Shareholders
Meeting_FR_FINAL eu
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Mag 2023 a Mag 2024
